I think the reason for the tempered response to the AE data is that, although it showed improvement, it still showed new AEs. My understanding is that AEs specifically pulmonary/coronary type AEs typically develop early in treatment. The fact that new ones continue occur in patients who have been on the drug for a significant time period is concerning and although dose reduction did help, New AEs still appear. This isn't a threat to the current approved indications but it is problematic for moving to earlier indications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.